Where to find the 5 Prime Sciences team at ASHG 2026
🎤 Talk | Thursday, Oct 22
Matt Tudball : “Trial entry, not genetics: collider bias can create apparent PRS-modified treatment response” at 2:15 PM This will take place in the following session: “Leveraging Pharmacogenomics for Drug Trial-Level Evidence.” (Room 520ABDE, Level 5 from 1:30 PM-2:30 PM).
📍 Posters | Wednesday, Oct 21, 2:30–4:30 PM
Marie Sadler: PRIMESuspect, using human genetics to identify the drug targets most likely to succeed to market (Board 5021W)
Kelly Agnew: Centromere, an end-to-end genetics platform for drug target discovery (Board 4021W)
Sahir Bhatnagar: Genetically mapping inter-tissue signaling to prioritize human drug targets (Board 8410W)
Alec McKinlay: Out-of-sample LD fine-mapping, a benchmarking analysis for algorithm selection, reference panel evaluation, and variant prioritisation (Board 8444W)
📍 Poster | Thursday, Oct 22, 4:15–6:15 PM
Kevin Liang: MOSAIC, hypothesis-free discovery of latent molecular components from GWAS summary statistics (Board 8426T)
RELATED
Dr. Brent Richards discusses with Amber Hayes why drug development is often aimed at the wrong problem
The Genetics PodCast: Triangulating genetic evidence and dodging bias to pick winning drug targets with Brent Richards of 5 Prime Sciences
Peter Kruczkiewicz joins as Software Engineer (Bioinformatics)
Peter brings over a decade of experience building bioinformatics tools and pipelines, most recently at the Public Health Agency of Canada, where he developed open-source workflows including the widely-used SISTR tool. He will focus on designing and integrating Nextflow pipelines at 5Prime.